The oncolytic effects of reovirus in canine solid tumor celllines

Journal of Veterinary Medical Science

Masaya IGASE¹  Masaru OKUDA³  Matt COFFEY⁴  Takuya MIZUNO¹  Shunsuke NOGUCHI¹  Chung Chew HWANG² 

[1] Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753�?8515, Japan;Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753�?8515, Japan;Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753�?8515, Japan;Oncolytics Biotech Inc., Calgary, Alberta, Canada

关键词: cancer;    canine;    oncolytic virotherapy;    reovirus;    solid tumor;   

DOI  :  10.1292/jvms.14-0570

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(33)Cited-By(1)Oncolytic virotherapy is a new strategy for cancer treatment for humans anddogs. Reovirus has been proven to be a potent oncolytic virus in human medicine. Ourlaboratory has previously reported that canine mast cell tumor and canine lymphoma weresusceptible to reovirus. In this study, canine solid tumor cell lines (mammary glandtumor, osteosarcoma and malignant melanoma) were tested to determine their susceptibilitytowards reovirus. We demonstrated that reovirus induces more than 50% cell death in threecanine mammary gland tumors and one canine malignant melanoma cell line. Thereovirus-induced cell death occurred via the activation of caspase 3. Ras activation hasbeen shown to be one of the important mechanisms of reovirus-susceptibility in humancancers. However, Ras activation was not related to the reovirus-susceptibility in caninesolid tumor cell lines, which was similar to reports in canine mast cell tumor and caninelymphoma. The results of this study highly suggest that canine mammary gland tumor andcanine malignant melanoma are also potential candidates for reovirus therapy in veterinaryoncology.

【 授权许可】

Unknown